Key Performance
More- Earnings Score: 13
- Momentum Score: 34
- True Yield: N/A
- Financial Health Score: 93
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Capricor Therapeutics faces a securities class action lawsuit alleging materially misleading statements regarding clinical trial data for its lead drug candidate deramiocel. The company's stock crashed 64% after FDA briefing documents revealed undisclosed modifications to the statistical analysis plan for the HOPE-3 study, which failed to meet pre-specified primary and secondary efficacy endpoints. Investors with losses between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status.
09/26/2026, 1:26 PM • GlobeNewswire
Faruqi & Faruqi, LLP is investigating securities fraud claims against Capricor Therapeutics for allegedly making misleading statements about its Deramiocel drug's regulatory prospects. The company allegedly failed to disclose changes to its statistical analysis plan and lack of FDA agreement before resubmitting the Biologics License Application. Capricor's stock plummeted 64% on July 27, 2026, after the FDA released unfavorable briefing documents, and fell an additional 36% on July 30, 2026, following an AdCom panel's 9-3 vote against the drug's efficacy. Investors who purchased securities between December 17, 2025 and July 26, 2026 may be eligible to participate in the class action lawsuit, with a September 28, 2026 deadline to seek lead plaintiff status.
09/26/2026, 8:56 AM • GlobeNewswire
Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against Capricor Therapeutics for making false and misleading statements regarding its Deramiocel drug candidate. The company allegedly changed its statistical analysis plan without FDA approval before resubmitting its Biologics License Application, creating significant risk of non-approval. The class period spans December 17, 2025 to July 26, 2026, with a September 28, 2026 deadline for investors to participate.
09/24/2026, 9:35 AM • GlobeNewswire
A class action lawsuit has been filed against Capricor Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its Deramiocel drug candidate. The complaint claims Capricor changed its statistical analysis plan for clinical data without FDA approval before resubmitting its Biologics License Application, creating significant risk of regulatory rejection. Investors who purchased Capricor securities between December 17, 2025 and July 26, 2026 are eligible to join the lawsuit.
09/23/2026, 12:00 PM • GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Capricor Therapeutics, Inc. Investors
A class action lawsuit has been filed against Capricor Therapeutics on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made undisclosed changes to its statistical analysis plan for its lead drug candidate Deramiocel without FDA approval, leading to FDA concerns about the validity of clinical results. Following FDA briefing documents released on July 27, 2026, Capricor's stock fell 64%, and after an advisory committee voted 9-3 against the drug's efficacy on July 30, the stock fell an additional 36%.
09/22/2026, 12:53 PM • GlobeNewswire
Hagens Berman has expanded a securities fraud class action lawsuit against Pentair plc, alleging the company made materially false statements about its financial health and channel inventory from March 11, 2025 to July 14, 2026. On July 14, 2026, Pentair shocked investors with a massive revenue miss ($930M vs. $1.14B forecast), revealed $170M in Pool segment inventory destocking, slashed full-year guidance, and announced the sudden departure of its CFO after only four months. The stock plummeted 15% the following day. Investors with substantial losses have until October 2, 2026 to become lead plaintiffs.
09/19/2026, 4:42 PM • GlobeNewswire
Hagens Berman notifies Capricor Therapeutics investors of a September 28, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges the company made materially false statements about clinical trial data for its drug deramiocel, failing to disclose undisclosed changes to the statistical analysis plan. After the FDA revealed the HOPE-3 study did not meet pre-specified endpoints, Capricor's stock crashed 64% on July 27, 2026.
09/19/2026, 4:41 PM • GlobeNewswire
Kahn Swick & Foti, LLC announces a class action securities lawsuit against Capricor Therapeutics for failing to disclose material information regarding changes to its statistical analysis plan for its lead drug candidate Deramiocel. The FDA found the company made undisclosed modifications to the analysis plan just before data unblinding, which the agency deemed post-hoc and exploratory. Following FDA briefing documents on July 27, 2026, Capricor's stock plummeted 64% to $7.00 per share. Investors who purchased shares between December 17, 2025 and July 26, 2026 can apply to join the lawsuit by September 28, 2026.
09/15/2026, 10:30 PM • GlobeNewswire
Law firm Kirby McInerney LLP announced pending securities class action lawsuits against Bloom Energy Corporation for allegedly making false statements about its reliance on Chinese scandium supplies. A short-seller report on July 8, 2026 revealed that Bloom Energy sourced scandium from China through intermediaries despite claiming minimal China supply chain dependence, causing the stock to fall 5.7%. The firm is seeking lead plaintiffs with a September 28, 2026 deadline.
09/15/2026, 6:00 PM • GlobeNewswire
Law firm Kirby McInerney LLP is alerting investors about pending securities fraud class action lawsuits against Capricor Therapeutics, Rackspace Technology, and Bloom Energy. The primary focus is on Capricor, which faces allegations of making false statements regarding changes to its statistical analysis plan for the Deramiocel drug candidate without FDA approval. The FDA subsequently rejected the drug, causing Capricor's stock to plummet 64% on July 27, 2026, and an additional 36% on July 30, 2026. The lead plaintiff deadline is September 28, 2026.
09/15/2026, 6:00 PM • GlobeNewswire
A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements about its Deramiocel cell therapy between December 2025 and July 2026. The FDA's briefing documents criticized the company's statistical analysis methods, and an advisory panel voted 9-3 against the therapy's efficacy, causing the stock to plummet 62% on July 27, 2026. Investors who purchased shares during the class period are urged to file claims by September 28, 2026.
09/14/2026, 12:55 PM • GlobeNewswire
Rosen Law Firm reminds investors in Capricor Therapeutics, Inc. (CAPR) of the September 28, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Capricor made false statements regarding changes to statistical analysis plans for its Deramiocel treatment without FDA approval, creating substantial risk of regulatory rejection and misleading investors about the company's prospects.
09/13/2026, 10:20 AM • GlobeNewswire
Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Capricor Therapeutics, which allegedly made false statements about its Deramiocel cell therapy by failing to disclose changes to statistical analysis plans and lack of FDA agreement before resubmitting its Biologics License Application. The lead plaintiff deadline is September 28, 2026. Additional lawsuits involve Innventure, Inc. and Planet Fitness, Inc.
09/13/2026, 10:20 AM • GlobeNewswire
Rosen Law Firm alerts investors in Capricor Therapeutics (CAPR) who purchased securities between December 17, 2025 and July 26, 2026 of an important September 28, 2026 deadline to join a securities class action. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA agreement, creating significant regulatory approval risks that were not properly disclosed to investors.
09/10/2026, 5:54 PM • GlobeNewswire
Capricor Therapeutics faces a securities fraud class action lawsuit alleging the company made false statements about its lead product Deramiocel and misrepresented clinical data integrity in its FDA Biologics License Application. The lawsuit was triggered by a 64.5% stock drop on July 27, 2026, following FDA briefing documents that raised concerns about post-hoc changes to the statistical analysis plan. Investors have until September 28, 2026 to request lead plaintiff status.
09/09/2026, 6:36 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/21/2026
Company Profile
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.